Clinical trials · New York, NY
Hodgkin Lymphoma clinical trials in New York
We’re tracking 71 recruiting hodgkin lymphoma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06876662RecruitingPhase 4
Continuing pirtobrutinib for CLL and lymphoma patients
This trial continues to give pirtobrutinib to people with chronic lymphocytic leukemia or certain other lymphomas who were already in a previous study with this drug. It helps researchers keep track of long-term safety and how well the drug works over time.
New York, New YorkAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
New York, New YorkAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
New York, New YorkAges 18 years+ - NCT06876649RecruitingPhase 4
Long-term safety study of Pirtobrutinib
This trial is for people who are already in a Lilly study taking pirtobrutinib. It looks at the long-term safety of the drug by continuing to monitor you.
New York, New YorkAges 18 years+ - NCT06745076RecruitingPhase 2
Personalized chemotherapy reduction for advanced Hodgkin lymphoma
This trial tests a personalized approach to using a blood test (ctDNA) to decide how much chemotherapy you need. If you have advanced Hodgkin lymphoma, this study might let you have less chemo if the blood test shows a strong response early on, potentially reducing side effects.
New York, New YorkAges 18 years+ - NCT07226843RecruitingPhase 1
Study of a new drug for adults with certain blood cancers
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
New York, New YorkAges 18 years+ - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
New York, New YorkAges 6 months–30 years - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
New York, New YorkAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
New York, New YorkAges 18 years+ - NCT06137144RecruitingPhase 1/Phase 2
AZD3470 for lymphoma that has come back or not responded
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
New York, New YorkAges 12 years+ - NCT07283822RecruitingPhase 2
Pembrolizumab and Ruxolitinib for Lymphoma
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
New York, New YorkAges 18–95 - NCT05783609RecruitingPhase 2
Epcoritamab and rituximab for untreated follicular lymphoma
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
New York, New YorkAges 18 years+ - NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
New York, New YorkAges 18–100 - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
New York, New YorkAges 18 years+ - NCT06098430Recruiting
Quality of life in NLPHL patients
This study looks at how people with a rare type of Hodgkin lymphoma (NLPHL) feel about their health and quality of life. By filling out surveys, you can help doctors understand what really matters to patients like you.
New York, New YorkAges 8 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
New York, New YorkAges Any age - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
New York, New YorkAges 18 years+ - NCT06563596RecruitingPhase 2
Study of epcoritamab, zanubrutinib, and rituximab for relapsed lymphoma
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
New York, New YorkAges 18 years+ - NCT02332668RecruitingPhase 1/Phase 2
Pembrolizumab for children with advanced, hard-to-treat cancer
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
New York, New YorkAges 6 months–17 years - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
New York, New YorkAges 18 years+ - NCT04685616RecruitingPhase 3
Testing brentuximab with standard chemo for early Hodgkin lymphoma
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
New York, New YorkAges 16–69 - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
New York, New YorkAges 12 years+ - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
New York, New YorkAges 18 years+
Hear when a new Hodgkin Lymphoma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Hodgkin Lymphoma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting hodgkin lymphoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 14 studies
- Columbia University Irving Medical Center · 3 studies
- Memorial Sloan Kettering Basking Ridge · 3 studies
- Memorial Sloan Kettering Bergen · 3 studies
- Memorial Sloan Kettering Monmouth · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Memorial Sloan Kettering Westchester · 3 studies
- Hackensack University Medical Center · 2 studies
What taking part in a hodgkin lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting hodgkin lymphoma studies in New York.
Common questions
- Are there hodgkin lymphoma clinical trials near New York?
- Yes. We're currently tracking 71 recruiting hodgkin lymphoma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hodgkin lymphoma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hodgkin lymphoma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.